PARP
49 programs · 49 companies
Programs
49
Companies
49
Active Trials
27
Targeting PARP
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | DravetBreast Ca | |
| NVO-2974 | Novo Nordisk | NDA/BLA | ETMCL | |
| Semainavolisib | Gilead Sciences | Phase 2 | WM | |
| REG-861 | Regeneron | Phase 2 | SLEThymoma | |
| CRS-337 | CRISPR Therapeutics | Phase 2/3 | PVPTSD | |
| Lisonesiran | Arvinas | Phase 1/2 | MyelofibrosisTTR Amyloidosis | |
| Olpavorutinib | BioArctic | Preclinical | EoENarcolepsy | |
| DAN-IIT-767 | Dana-Farber | NDA/BLA | SCLC | |
| MAY-IIT-361 | Mayo Clinic | Preclinical | MDS | |
| SAM-IIT-450 | Samsung Medical Ctr | Phase 2/3 | NB | |
| PEK-IIT-569 | Peking Univ Cancer Hosp | Preclinical | PAH | |
| FRE-IIT-874 | Fred Hutch Cancer Ctr | NDA/BLA | NMOSD | |
| GIM-IIT-646 | GIMEMA | Phase 3 | PsA | |
| SEA-4335 | Seagen (Pfizer) | Phase 3 | PompeET | |
| Polatinib | Karuna (BMS) | Phase 1 | PBCOvarian Ca | |
| ONC-9948 | OncXerna | Approved | Crohn'sGIST | |
| Sotorapivir | Selecta Bio | Phase 1 | NMOSDSMA | |
| SYR-7044 | Spyre Ther | Phase 3 | NASHPsA | |
| Kemaratamab | Nurix Ther | Phase 1/2 | AMLDLBCL | |
| FOR-7299 | Forma Therapeutics | Phase 3 | SLEUrothelial Ca | |
| NDR-1720 | ENDRA Life Sciences | Phase 3 | Huntington's | |
| CLO-7126 | Clovis Oncology | Preclinical | WilmsNB | |
| AMP-8001 | Ampio Pharma | NDA/BLA | TTR AmyloidosisAsthma | |
| Voxatapinarof | MyoKardia (BMS) | Phase 2 | LNOvarian Ca | |
| Elracapivasertib | Proteon (Charles River) | NDA/BLA | ALL | |
| CLE-136 | Clementia (Ipsen) | Phase 3 | PAHACC | |
| Pexaderotide | Caris Life Sci | Phase 3 | PNHCholangiocarcinoma | |
| Doxazanubrutinib | Terray Ther | Phase 3 | SchizophreniaGA | |
| CEL-1794 | Cellarity | Approved | OCDNMOSD | |
| KOD-8391 | Kodiak Sci | Phase 2/3 | MesoEoE | |
| Nirarasimod | Rapafusyn | Phase 2/3 | NMOSDLN | |
| Gozenesiran | Hyku Bio | NDA/BLA | LGSPTSD | |
| YB-4895 | Y-Biologics | Phase 1/2 | RB | |
| Motazumab | Vivoryon | Phase 3 | FabryRCC | |
| Mirinesiran | Blau Farmaceutica | Preclinical | Huntington's | |
| Datofotisoran | Insud Pharma | Phase 1/2 | MCC | |
| Surasertib | Duopharma | Phase 2 | ACCHuntington's | |
| VIN-2751 | Vingroup Biotech | Phase 2/3 | MDDSchizophrenia | |
| Rimavorutinib | Thai Otsuka | Phase 3 | ACCProstate Ca | |
| Gelifutibatinib | Julphar | Approved | WMMS | |
| TEV-6161 | Teva Pharma | Preclinical | Crohn'sEoE | |
| PET-IIT-181 | Peter MacCallum | Approved | LGS | |
| SEV-IIT-824 | Severance Hospital | Phase 2 | SCD | |
| NAT-IIT-326 | Natl Taiwan Univ Hosp | Phase 1/2 | MS | |
| KIN-IIT-300 | King Faisal Spec Hosp | Phase 2/3 | Pompe | |
| Adagraosocimab | Agilent Technologies | Approved | Melanoma | |
| Miriglumide | IDEXX Laboratories | NDA/BLA | IPFNMOSD | |
| Bemacagene | Codexis | Phase 2/3 | NarcolepsyAtopic Derm | |
| Tezeglumide | Certara | Phase 1/2 | Urothelial CaIPF |